​

Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TRDA Stock Forecast

Entrada Therapeutics (TRDA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 20.15% increase from the last price of $10.82.

$10 $12 $14 $16 $18 $20 High: $13 Avg: $13 Low: $13 Last Closed Price: $10.82

TRDA Stock Rating

Entrada Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

TRDA Price Target Upside V Benchmarks

TypeNameUpside
StockEntrada Therapeutics20.15%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$13.00$18.00
Last Closing Price$10.82$10.82$10.82
Upside/Downside-20.15%66.36%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-5---5
Nov, 2513---4
Oct, 2513---4
Sep, 2513---4
Aug, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2025Roth Capital$13.00$6.9587.05%20.15%
Feb 28, 2025Roth Capital$23.00$11.9492.63%112.57%
Nov 06, 2024Boobalan PachaiyappanH.C. Wainwright$20.00$18.0310.93%84.84%
Jun 25, 2024Raghuram SelvarajuH.C. Wainwright$18.00$14.2426.40%66.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024Cowen & Co.BuyBuyhold
Jun 25, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024Cowen & Co.BuyBuyhold
Nov 22, 2023William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.20$1.76----
Avg Forecast$-0.09$1.05$-3.09$-3.17$-4.50$-4.75
High Forecast$4.13$1.18$-2.66$-2.58$-3.11$-3.28
Low Forecast$-2.63$0.91$-3.58$-3.76$-6.07$-6.40
Surprise %122.22%67.62%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$129.01M$210.78M----
Avg Forecast$110.88M$186.51M$46.74M$47.86M$174.22M$304.77M
High Forecast$119.28M$189.22M$58.45M$60.66M$220.83M$386.31M
Low Forecast$97.65M$184.74M$36.26M$36.47M$132.78M$232.28M
Surprise %16.35%13.01%----

Net Income Forecast

$-250M $-170M $-90M $-10M $70M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.68M$65.63M----
Avg Forecast$-6.68M$34.63M$-103.05M$-104.79M$-151.60M$-156.99M
High Forecast$136.35M$39.14M$-87.88M$-85.16M$-102.74M$-108.44M
Low Forecast$-87.03M$30.13M$-118.22M$-124.43M$-200.45M$-211.59M
Surprise %-89.48%----

TRDA Forecast FAQ

Is Entrada Therapeutics stock a buy?

Entrada Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Entrada Therapeutics is a favorable investment for most analysts.

What is Entrada Therapeutics's price target?

Entrada Therapeutics's price target, set by 5 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 20.15% change from the previous closing price of $10.82.

How does Entrada Therapeutics stock forecast compare to its benchmarks?

Entrada Therapeutics's stock forecast shows a 20.15% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Entrada Therapeutics over the past three months?

  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Entrada Therapeutics’s EPS forecast?

Entrada Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.09, marking a -275.57% decrease from the reported $1.76 in 2024. Estimates for the following years are $-3.17 in 2026, $-4.5 in 2027, and $-4.75 in 2028.

What is Entrada Therapeutics’s revenue forecast?

Entrada Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $46.74M, reflecting a -77.83% decrease from the reported $210.78M in 2024. The forecast for 2026 is $47.86M, followed by $174.22M for 2027, and $304.77M for 2028.

What is Entrada Therapeutics’s net income forecast?

Entrada Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-103M, representing a -257.02% decrease from the reported $65.63M in 2024. Projections indicate $-105M in 2026, $-152M in 2027, and $-157M in 2028.